← Back
$ALNY All transactions

ALNYLAM PHARMACEUTICALS, INC.

▼ SELL

$ Value

$1K

Shares

3

Price

$458

Filed

Oct 3

Insider

Name

Fitzgerald Kevin Joseph

Title

CSO & EVP, Head of Research

CIK

0001886431

Roles

Officer

Transaction Details

Transaction Date

2025-10-02

Code

S

Table

Non-Derivative

Ownership

Direct

Equity Swap

No

Shares After

25,231

Footnotes

On February 24, 2021, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of four specified performance measures. The shares reported were issued to the reporting person upon vesting of one-quarter of the shares subject to the PSU based on the issuer publicly reporting the initiation of a Phase 3 clinical study of an RNAi therapeutic in development to treat a prevalent disease, as determined by the People, Culture and Compensation (PC&C) Committee of the Issuer Board of Directors on October 1, 2025. | On March 1, 2024, the reporting person was granted a PSU under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of thirty (30) percent of the shares subject to the PSU based on the issuer publicly reporting the initiation of a Phase 3 clinical study in a prevalent indication, as determined by the PC&C Committee on October 1, 2025. | Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024. | The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $446.19 to $447.19. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. | The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $447.21 to $448.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. | The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $448.25 to $449.24. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. | The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $449.26 to $450.26. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. | The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $450.29 to $451.29. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. | The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $451.31 to $452.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. | The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $452.33 to $453.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. | The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $453.37 to $454.37. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. | The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $454.38 to $455.34. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. | The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $455.42 to $456.09. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. | Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.

Filing Info

Accession No.

0001735276-25-000114

Form Type

4

Issuer CIK

0001178670

Fitzgerald Kevin Joseph's History

Date Ticker Type Value
2026-04-07 OVID A $45K
2026-03-05 ALNY $40K
2026-03-05 ALNY $75K
2026-03-05 ALNY $48K
2026-03-05 ALNY $50K
2026-03-04 ALNY $9K
2026-03-04 ALNY $9K
2026-03-04 ALNY $19K
2026-03-04 ALNY $25K
2026-03-04 ALNY $31K

Other Insiders at ALNY (90d)

Insider Bought Sold Last
Greenstreet Yvonne
Chief Executive Officer
$5.3M 2026-03-04
SUPRAN BRYAN
EVP, CLO and Secretary
2026-03-02
Poulton Jeffrey V.
EVP, Chief Financial Officer
$2.2M 2026-03-04
Garg Pushkal
EVP Chief R&D
$4.9M 2026-03-05
Tanguler Tolga
EVP, Chief Commercial Officer
$1.9M 2026-03-04
Fitzgerald Kevin Joseph
CSO & EVP, Head of Research
$2.8M 2026-03-05
McLaughlin Melissa
Chief Human Resources Officer
$1.3M 2026-04-06